The fresh capital is primarily intended to finance the clinical development of the company’s own cancer drugs, as well as their manufacture and potential future commercialisation. Immatics focuses on immunotherapies targeting the tumour antigen PRAME, which is present in numerous types of cancer. The pipeline comprises both cell therapies and bispecific T-cell receptors.
Following completion of the transaction and the full exercise of the additional share option, the net proceeds ultimately amounted to around 161 million dollars. For Immatics, the funding represents a further step towards driving forward capital-intensive clinical development under its own steam. At the same time, the transaction underlines the importance of the US capital market for European biotech companies. Particularly for clinical platforms, access to larger rounds of funding determines how many programmes can be developed in parallel and financed until decisive trial data is available.
Press release from “Immatics” dated 25 August 2026